Personalis (PSNL) CEO Christopher Hall Sells 100,000 Shares

Christopher Hall, the Chief Executive Officer of Personalis, Inc. (NasdaqGM: PSNL), sold 100,000 shares of the company on June 26, 2026. This transaction was not part of a pre-planned trading program, according to the latest filings.

Insider Buying and Selling at Personalis, Inc.

On the same day, Aaron Tachibana, the CFO and COO, also transacted shares. Tachibana purchased 51,251 shares at an average price of $7.48 and sold another 51,251 shares at $13.18 under a planned sale. Christopher Hall's sale at an undisclosed price was not planned, marking a significant insider activity within the company.

Personalis, Inc. Stock Down 20.6%

Shares of Personalis, Inc. traded near $13.02 on Saturday. The company, with a market cap of approximately $1.36 billion, operates in the healthcare sector, specializing in diagnostics and research. It has a beta of 2.276, indicating higher volatility compared to the market. The stock's 52-week range is between $3.84 and $13.37, with moving averages of $8.27 over 50 days and $8.21 over 200 days. The company holds a strong current ratio of 6.613, reflecting its ability to cover short-term obligations.

Analysts Set New Price Targets

Analysts have maintained their ratings on Personalis with varied target prices. On May 12, 2026, Morgan Stanley maintained a 'hold' rating with a target price of $9. BTIG, on May 11, 2026, maintained its 'buy' rating, setting a target price of $11. The consensus among analysts suggests a mean target price of $10.86, reflecting mixed sentiment about the stock's future performance.

About Personalis, Inc.

Personalis, Inc., headquartered in Fremont, California, is a healthcare company that specializes in developing and marketing advanced cancer genomic tests. These tests aid in the detection of minimal residual disease, therapy response, and recurrence monitoring in solid tumor cancers. The company serves a wide range of clients, including pharmaceutical and diagnostics companies, universities, and government entities. Under the leadership of CEO Christopher Hall, Personalis employs 259 people and collaborates with Tempus AI, Inc. to enhance cancer testing.

Bottom Line

The recent insider transactions at Personalis, Inc. highlight significant movements within its executive team. Investors often watch such activities closely as they can offer insights into the confidence levels of insiders. While Christopher Hall's recent sale of shares is notable, it's important to remember that such transactions can occur for a variety of reasons not necessarily related to the company's performance. Analysts remain divided on the stock's outlook, with target prices reflecting a range of expectations.